Section of Rheumatology
Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730
|MD||1976||University of Illinois||
|Residency||1980||National Naval Medical Center||Internal Medicine
|Fellowship||1982||The University of Chicago||Rheumatology
Dr. Curran has had an interest in the diagnosis and natural history of late onset (onset after age 60) rheumatoid arthritis. He published the initial 50 cases of the entity in Seminars of Arthritis & Rheumatism 1992, defining the therapeutic requirements and clinical outcomes. He currently is involved in studies using IL6 and Rituxan for advanced and aggressive rheumatoid arthritis. Dr. Curran also has an interest in treating inflammatory muscle disease, especially polymyositis and dermatomyositis associated with synthetase antibodies and systemic vascultides. He is also researching the use of combinations of immunosuppressive medications in the treatment of primary Sjogren’s syndrome.
Late onset rheumatoid arthritis and aggressive treatment, resistant RA, Sjogren’s syndrome, polymyositis and dermatomyositis, sarcoidosis,mixed connective tissue disease and systemic vasculitis.
- Mileti LM, Strek ME, Curran JJ, Sweiss NJ: Clinical Characteristics of Patients with Anti-Jo-1 Antibodies: A Single Center Experience: Journal of Clinical Rheumatology, 2009.
- Jolly M, Ellman M, Curran JJ.Benign angiopathy of the central nervous system. Journal of Clinical Rheumatology. 10(2):80-82, April 2004.
- Nadera J. Sweiss, Michael Jude Welsch, James J. Curran, Michael H. Ellman. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Care & Research. 53(5): 788-791, Oct 2005.
- Jolly M, Sweiss N, Curran JJ: Underuse of intra and periarticular corticosteroid injections among primary care physicians. Journal of Clinical Rheumatology, 9(3), 187-192, 2003.
- Jolly, M, Curran JJ: Infliximab-Responsive Uvetis and Vasculitis in a Patient with Takayasu Arteritis. Journal of Clinical Rheumatology. 11(4):213-215, August 2005